pharma
The latest news about pharma: headlines, AI summaries and the full story from every source.
- AbbVie releases phase 3 induction therapy data on injectable Skyrizi for Crohn's
- Bristol Myers Squibb Shares Rise on Positive Phase 3 Trial Results
- Roche partners with Chinese startup for drug discovery in nearly $1 billion deal
- Enliven and FDA Agree on Phase 3 Trial Design for Relcobatinib in Chronic Myeloid Leukemia
- Gossamer Bio Submits NDA for Seralutinib in Pulmonary Arterial Hypertension
- Alkermes Shares Rise on Positive Phase 1b Results for ALKS 7290
- Novo Nordisk Rebrands as Novo and Partners with Anthropic to Accelerate Drug Discovery in Diabetes and Obesity
- Amgen Stock Drops Sharply Amid Novartis' Lp(a)-Lowering Drug Failure
- Thermo Fisher Scientific Raises Outlook, Forecasts Strong Growth in 2026
- Gilead Expands HIV Drug Access to Latin America via PAHO Agreement
- Evommune Discontinues Eczema Candidate EVO756; Focus Shifts to EVO301
- Tectonic Therapeutic Completes Key Clinical Trial Milestones
- Premarket Stock Movements: Peloton, Roivant Sciences, Boston Scientific Among Major Movers
- Guggenheim Downgrades Alumis Following Mid-Stage Trial Setback
- Summit Therapeutics' Lung Cancer Drug Shows Survival Benefit
- Tenax Therapeutics Reports Subgroup Benefit Despite Phase 3 Trial Missing Primary Endpoint
- ADC Therapeutics Faces FDA Concerns Over ZYNLONTA Combination While Reducing Losses
- Leo Pharma Acquires Rights to Experimental Rare Skin Disease Drug in $435M Deal
- AptarGroup Reports Record Q2 Sales but Faces EBITDA Margin Decline
- Karyopharm's Xpovio Fails Phase 3 Trial for Endometrial Cancer, Shares Plummet
- Pharming Group Q2 Earnings Call: Revenue Falls, Outlook Cut Amid Market Shifts
- Pharming Reports Q2 GAAP EPS of $0.00 and Revenue Misses Estimates
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal; Cathie Wood Shifts Focus to Compass Pathways
- Omeros Gains as AstraZeneca's Ultomiris Fails in Rare Blood Disorder Trial
- Summit Therapeutics Reports Stronger Survival Benefits for Lead Cancer Drug in Extended Follow-Up
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion in Psychedelic Drug Development
- Sellas Life Sciences (SLS) Rises Ahead of Upcoming Clinical Trial Results
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion, Expanding Psychedelic Drug Portfolio
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
- Silo Pharma Announces NVIDIA Partnership for AI Platform and Advances PTSD Treatment Development
- Biohaven Completes Enrollment in RISE3 Trial for Opakalim
- Two Biotech Stocks Considered Potential Buyout Targets
- AstraZeneca's CARES Phase III Clinical Programme Fails to Meet Primary Endpoint
- Cognition Therapeutics (CGTX) Discusses Path Toward Registrational Trial for Dementia With Lewy Bodies
- Ironwood Pharmaceuticals Expands Pediatric Approval for Linzess
- Bristol-Myers Squibb Partners with Anthropic to Expand AI Capabilities
- BioMarin's Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint
- Evogene Ltd. Q1 2026 Earnings Call Summary
- Roivant Sciences Rises on Positive Phase 2 Trial Data from Immunovant's Drug
- Gossamer Bio Outlines Regulatory and Financial Plans in Q1 Earnings Call
- Gossamer Bio Reports Q1 GAAP EPS of -$0.20, Revenue Exceeds Expectations
- Regeneron Announces Failure in Late-Stage Trial of Libtayo Combination Therapy
- Imunon (IMNN) Q1 2026 Earnings Call Summary
- Bicara (BCAX) Q1 2026 Earnings Call Summary
- EyePoint Reports Q1 2026 Earnings and Clinical Progress
- Bio-Techne (TECH) Reports Q3 2026 Earnings with Revenue Decline and Adjusted EPS Drop
- Geron Reports Q1 Revenue Growth of $61.8M and Reiterates Full-Year Guidance
- Moderna Reports Q1 2026 Earnings with Revenue Growth and Strategic Milestones
- Zoetis Inc. Expands Capabilities of Vetscan OptiCell Hematology Analyzer
- Cardinal Health Reports Strong Pharma Segment Growth Amid IRA Pricing Adjustments